Status:
UNKNOWN
Safety and Feasibility of Allogenic MSC in the Treatment of COVID-19
Lead Sponsor:
Hospital de Clinicas de Porto Alegre
Conditions:
COVID-19
Sars-CoV2
Eligibility:
All Genders
Phase:
PHASE1
Brief Summary
Coronavirus Disease 2019 (COVID-19) is spreading worldwide and has become a public health emergency of major international concern. Currently, no specific drugs or vaccines are available. For severe c...
Detailed Description
Coronavirus-19 Disease (COVID-19), caused by the Sars-Cov-2 virus, which occurs as a growing pandemic in early 2020 and currently represents an emergency state worldwide. Several reports have shown th...
Eligibility Criteria
Inclusion
- Laboratory confirmation of COVID19 infection by reverse-transcription polymerase chain reaction (RT-PCR)
- The patient or legal donor agrees to participate in the study and signs the informed consent.
- Patients with orange or red criteria according to the score proposed by Liao et al (2020)
Exclusion
- Patient with pregnancy, are planning to become pregnant or breastfeeding
- Patients with malignant blood-borne diseases such as HIV or syphilis
- Not consenting for clinical trial
- Patients with other than orange or red criteria according to the score proposed by Liao et al (2020)
Key Trial Info
Start Date :
July 25 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 30 2020
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT04467047
Start Date
July 25 2020
End Date
December 30 2020
Last Update
July 10 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.